检索范围:
排序: 展示方式:
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang
《医学前沿(英文)》 2020年 第14卷 第6期 页码 711-725 doi: 10.1007/s11684-020-0808-3
关键词: chimeric antigen receptor T (CAR-T) cell lymphoma cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity syndrome (ICANS)
《医学前沿(英文)》 2023年 第17卷 第4期 页码 699-713 doi: 10.1007/s11684-022-0972-8
关键词: anti-CD19 chimeric antigen receptor T immunotherapy diffuse large B cell lymphoma tumor microenvironment tumor-associated macrophage metabolism
Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang
《医学前沿(英文)》 2020年 第14卷 第6期 页码 786-791 doi: 10.1007/s11684-020-0751-3
关键词: anti-CD19 chimeric antigen receptor T cell soft tissue bone marrow relapsed or refractory non-Hodgkin lymphoma
Chimeric antigen receptor T cell therapies for acute myeloid leukemia
Bin Gu, Jianhong Chu, Depei Wu
《医学前沿(英文)》 2020年 第14卷 第6期 页码 701-710 doi: 10.1007/s11684-020-0763-z
Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy
Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen
《医学前沿(英文)》 2019年 第13卷 第1期 页码 57-68 doi: 10.1007/s11684-019-0683-y
Lung cancer is the most common incident cancer and the leading cause of cancer death. In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-T) cell has shown a promising future. Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation expressed in various types of tumors and has been detected in non-small cell lung cancer with a mutation rate of 10%. Thus, EGFRvIII is a potential antigen for targeted lung cancer therapy. In this study, CAR vectors were constructed and transfected into virus-packaging cells. Then, activated T cells were infected with retrovirus harvested from stable virus-producing single clone cell lines. CAR expression on the surfaces of the T cells was detected by flow cytometry and Western blot. The function of CAR-T targeting EGFRvIII was then evaluated. The EGFRvIII-CAR vector was successfully constructed and confirmed by DNA sequencing. A stable virus-producing cell line was produced from a single clone by limited dilution. The culture conditions for the cell line, including cell density, temperature, and culture medium were optimized. After infection with retrovirus, CAR was expressed on more than 90% of the T cells. The proliferation of CAR-T cells were induced by cytokine and specific antigen in vitro. More importantly, EGFRvIII-CART specifically and efficiently recognized and killed A549-EGFRvIII cells with an effector/target ratio of 10:1 by expressing and releasing cytokines, including perforin, granzyme B, IFN-g, and TNF-α. The in vivo study indicated that the metastasis of A549-EGFRvIII cells in mice were inhibited by EGFRvIII-CART cells, and the survival of the mice was significantly prolonged with no serious side effects. EGFRvIII-CART showed significantly efficient antitumor activity against lung cancer cells expressing EGFRvIII in vivo and in vitro. Therefore, CAR-T targeting EGFRvIII is a potential therapeutic strategy in preventing recurrence and metastasis of lung cancer after surgery.
关键词: chimeric antigen receptor T cells epidermal growth factor receptor lung cancer immunotherapy tumor immunology
《医学前沿(英文)》 2022年 第16卷 第2期 页码 285-294 doi: 10.1007/s11684-021-0843-8
关键词: CAR-T cell therapy refractory diffuse large B-cell lymphoma cytokine release syndrome dose-limiting toxicity
Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang
《医学前沿(英文)》 2020年 第14卷 第6期 页码 811-815 doi: 10.1007/s11684-020-0740-6
关键词: anti-CD19 chimeric antigen receptor T cells mantle cell lymphoma relapsed or refractory long-term follow-up
Emerging immunological strategies: recent advances and future directions
《医学前沿(英文)》 2021年 第15卷 第6期 页码 805-828 doi: 10.1007/s11684-021-0886-x
关键词: cancer immunotherapy bispecific antibodies small molecules chimeric antigen receptor T therapy cancer vaccines
CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a
《医学前沿(英文)》 2022年 第16卷 第3期 页码 322-338 doi: 10.1007/s11684-021-0901-2
关键词: cancer immunotherapy chimeric antigen receptor solid tumors tumor-associated antigen glycosylation O-glycans adoptive cell therapy
Adoptive cell transfer therapy for hepatocellular carcinoma
Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen
《医学前沿(英文)》 2019年 第13卷 第1期 页码 3-11 doi: 10.1007/s11684-019-0684-x
关键词: adoptive cell transfer therapy hepatocellular carcinoma T cell chimeric antigen receptor immunotherapy
Development of oncolytic virotherapy: from genetic modification to combination therapy
Qiaoshuai Lan, Shuai Xia, Qian Wang, Wei Xu, Haiyan Huang, Shibo Jiang, Lu Lu
《医学前沿(英文)》 2020年 第14卷 第2期 页码 160-184 doi: 10.1007/s11684-020-0750-4
关键词: immunotherapy oncolytic virus genetic modification immune checkpoint blockade chimeric antigen receptor T cell
嵌合抗原受体和调节性T细胞——移植中人类白细胞抗原特异性免疫抑制的潜力 Review
Sabrina Wright, Conor Hennessy, Joanna Hester, Fadi Issa
《工程(英文)》 2022年 第10卷 第3期 页码 30-43 doi: 10.1016/j.eng.2021.10.018
嵌合抗原受体(CAR)是基因工程领域的一项突破,它彻底改变了过继细胞疗法(ACT)领域。表达这些受体的细胞通过在合成的CAR构建体中包含抗原特异性结合区域而被重新定向到预定的靶点。程序化特异性细胞在肿瘤学领域的优势已被临床证明,与同类未修饰的细胞相比,这种细胞具有更高的准确性、效力与更少的脱靶效应。与常规T细胞(Tconvs)不同,调节性T细胞(Treg)在抑制免疫激活和调节宿主免疫反应方面发挥着重要作用。Treg 中CAR的表达被认为是治疗自身免疫和炎症性疾病、移植物抗宿主病(GVHD)和器官移植排斥反应的一种方法。在后者中,它们作为同种异体移植受者免疫耐受的介质具有巨大的潜力。然而,目前对CAR-Treg 工程的研究非常有限,并且关于治疗用途的最佳设计存在不确定性。本文综述了CAR-Treg 发展的理论基础、其对人类移植的意义、潜在的设计、安全性考虑因素,以及迄今为止CAR-Treg在移植模型中的对比。
关键词: 嵌合抗原受体(CAR) 调节性T细胞 异性免疫 CAR设计 基因编辑
从药物开发的角度看工程化T细胞疗法 Review
Fang Chen, Joseph A. Fraietta, Carl H. June, 许中伟, J. Joseph Melenhorst, Simon F. Lacey
《工程(英文)》 2019年 第5卷 第1期 页码 140-149 doi: 10.1016/j.eng.2018.11.010
标题 作者 时间 类型 操作
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang
期刊论文
tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimericantigen receptor T therapy
期刊论文
involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimericantigen receptor T cell therapy
Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang
期刊论文
Chimeric antigen receptor T cell therapies for acute myeloid leukemia
Bin Gu, Jianhong Chu, Depei Wu
期刊论文
Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy
Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen
期刊论文
Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large
期刊论文
Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle
Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang
期刊论文
CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a
期刊论文
Adoptive cell transfer therapy for hepatocellular carcinoma
Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen
期刊论文
Development of oncolytic virotherapy: from genetic modification to combination therapy
Qiaoshuai Lan, Shuai Xia, Qian Wang, Wei Xu, Haiyan Huang, Shibo Jiang, Lu Lu
期刊论文